Trial Profile
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2023
Price :
$35
*
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Registrational; Therapeutic Use
- Acronyms ePHex
- Sponsors OxThera
- 01 Feb 2023 Results reporting long-term efficacy and safety published in the Pediatric Nephrology
- 14 Oct 2021 Planned number of patients changed from 22 to 25.
- 11 Jun 2021 Primary endpoint (Change from baseline in plasma oxalate concentration after 52 weeks of treatment) has not been met, according to an OxThera media release.